Renal Cell Carcinoma — Diagnosis, Evaluation & Management

Key Points

• RCC is usually detected incidentally but can present with hematuria, flank pain, metastatic symptoms, or paraneoplastic syndromes.
• Contrast-enhanced CT or MRI of the abdomen and pelvis is essential for characterization and staging of a renal mass.
• Partial nephrectomy is preferred for most T1 tumors to preserve renal function, while radical nephrectomy is reserved for large, complex, or locally advanced lesions.
• Percutaneous renal mass biopsy is recommended when results will influence management, particularly in the setting of indeterminate lesions, planned ablation, active surveillance, or systemic therapy.
• For metastatic RCC, first-line treatment is centered on immune checkpoint inhibitor–based combinations, with regimen choice guided by histology, risk group, comorbidities, and patient preference.
• Risk-adapted surveillance and comprehensive survivorship care, including management of renal function and cardiovascular risk, are integral to long-term outcomes.

Algorithm

1. Confirm solid or complex enhancing renal mass with contrast-enhanced CT or MRI and perform complete staging including chest imaging.
2. Assess patient performance status, comorbidities, renal function, and life expectancy.
3. For T1 tumors, prioritize partial nephrectomy when technically feasible to preserve renal function; consider thermal ablation or active surveillance for select small masses in high-risk surgical candidates or elderly patients.
4. For larger or more centrally located tumors not amenable to nephron-sparing surgery, perform radical nephrectomy with regional lymph node assessment when indicated.
5. In locally advanced RCC with venous tumor thrombus, consider radical nephrectomy with thrombectomy at experienced centers.
6. For metastatic RCC, obtain histologic confirmation and risk stratify using an accepted model; initiate first-line systemic therapy with an immune checkpoint inhibitor–based combination tailored to risk category and comorbidities.
7. Consider cytoreductive nephrectomy or metastasis-directed therapy in carefully selected patients with limited metastatic burden and good performance status after multidisciplinary discussion.
8. Implement stage-adapted surveillance imaging following local treatment or during systemic therapy to monitor for recurrence or progression.

Localized Disease Management

For clinical T1 tumors, partial nephrectomy is the preferred standard of care when anatomically feasible, as it provides excellent oncologic control while preserving renal parenchyma and reducing the risk of chronic kidney disease. Robotic or laparoscopic approaches are commonly used. Radical nephrectomy is indicated for large, centrally located, or locally advanced tumors that are not amenable to partial nephrectomy or when oncologic control would be compromised. In carefully selected patients with small renal masses, especially older individuals with limited life expectancy or significant comorbidities, active surveillance with serial imaging is acceptable. Minimally invasive ablative techniques such as cryoablation or radiofrequency ablation are options for T1a lesions in patients who are poor surgical candidates or prefer less invasive therapy, with the understanding that long-term local control data are more limited than with surgery.

Advanced and Metastatic Disease Management

Management of advanced and metastatic RCC is anchored in immune checkpoint inhibitor–based combinations and VEGF-targeted therapies. For clear cell RCC, contemporary first-line regimens include dual checkpoint blockade with nivolumab plus ipilimumab, or combinations of a PD-1 or PD-L1 inhibitor with a VEGF tyrosine kinase inhibitor such as pembrolizumab plus axitinib, nivolumab plus cabozantinib, or lenvatinib plus pembrolizumab. Regimen selection considers IMDC risk group, burden and tempo of disease, comorbidities, toxicity profiles, and patient preference. Subsequent-line options include other VEGF-TKIs, mTOR inhibitors, and newer agents such as HIF-2 alpha inhibitors where available. For non–clear cell histologies, evidence is more limited; VEGF-targeted therapy, MET inhibitors for papillary RCC, and immunotherapy combinations are used based on emerging data and guideline recommendations. Cytoreductive nephrectomy may be considered in well-selected patients with good performance status and limited metastatic burden, particularly when systemic therapy is controlling disease or when the primary tumor is symptomatic.

Epidemiology / Risk Factors

• RCC represents approximately 3–5% of adult malignancies and is the most common kidney cancer in adults.
• Peak incidence occurs between 60 and 70 years of age, with a male predominance.
• Established risk factors include cigarette smoking, obesity, hypertension, chronic kidney disease, and acquired cystic kidney disease.
• Hereditary syndromes associated with RCC include von Hippel–Lindau disease, hereditary leiomyomatosis and RCC, Birt–Hogg–Dubé syndrome, and hereditary papillary RCC.
• Incidence is higher in high-income countries and has risen with increased use of cross-sectional imaging.

Investigations

Staging & Risk Stratification Overview

Pharmacology

Prognosis / Complications

• Prognosis is primarily determined by stage, histologic features, and risk models incorporating performance status and laboratory parameters.
• Patients with small, localized T1 tumors treated with partial nephrectomy have excellent cancer-specific survival, often exceeding 95 percent at 5 years.
• Locally advanced disease with venous tumor thrombus or nodal involvement carries higher recurrence risk but can still be cured with complete surgical resection in a subset of patients.
• In metastatic RCC, median survival has improved substantially with modern immunotherapy and targeted regimens, and a proportion of patients achieve long-term durable responses.
• Structured, risk-adapted surveillance with periodic imaging of the chest and abdomen is recommended following definitive local therapy, with frequency tailored to recurrence risk and time from treatment.

Patient Education / Counseling

• Explain the nature of RCC, including histologic subtype, stage, and individualized prognosis, using clear language and visual aids when possible.
• Discuss treatment options including partial versus radical nephrectomy, ablative techniques, and systemic therapy, emphasizing trade-offs between cancer control, renal function, toxicity, and quality of life.
• Review potential short- and long-term complications, such as chronic kidney disease, cardiovascular risk, and treatment-specific adverse events, and outline monitoring and mitigation strategies.
• Encourage modification of risk factors including smoking cessation, weight optimization, blood pressure control, and regular physical activity as part of survivorship care.
• Highlight the importance of adherence to surveillance imaging schedules and clinic visits to detect recurrence or progression early and to manage chronic treatment effects.

Clinical Overview & Pathophysiology

Renal cell carcinoma (RCC) arises from renal tubular epithelium and accounts for more than 90% of primary renal malignancies. Clear cell RCC is the most common histologic subtype, followed by papillary, chromophobe, and other rare variants. Clear cell RCC is strongly associated with alterations in the VHL gene and dysregulation of hypoxia-inducible factor and VEGF pathways, contributing to its hypervascular nature. RCC often remains clinically silent until advanced stages; the classic triad of flank pain, hematuria, and palpable mass is now uncommon. Many tumors are detected incidentally on abdominal imaging performed for unrelated indications. Paraneoplastic syndromes are frequent and may manifest as erythrocytosis, anemia, hypercalcemia, hepatic dysfunction without metastases (Stauffer syndrome), or hypertension due to increased renin.

Clinical Presentation

Most RCCs are discovered incidentally on imaging performed for unrelated reasons, particularly small T1 tumors. Symptomatic disease may present with gross or microscopic hematuria, flank or abdominal pain, or a palpable mass. Constitutional symptoms such as weight loss, fever, night sweats, and fatigue can reflect advanced disease. Metastatic RCC commonly involves lung, bone, liver, brain, and distant lymph nodes, potentially causing cough, dyspnea, pathologic fractures, or neurologic deficits. Paraneoplastic manifestations including hypercalcemia, erythrocytosis, thrombocytosis, and hepatic dysfunction can be the first clue to an underlying RCC and should prompt imaging if no alternative explanation is found.

References

1. Hsieh JJ et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009. — Link
2. Motzer RJ et al. NCCN Guidelines Insights: Kidney Cancer, Version 2.2024. J Natl Compr Canc Netw. 2024;22(2):72-86. — Link
3. Bex A et al. European Association of Urology Guidelines on Renal Cell Carcinoma: 2025 Update. — Link